Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus.

ABSTRACT:

Aim

To confirm the efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus inadequately controlled with pioglitazone monotherapy.

Materials and methods

In an initial 12-week, double-blind, placebo controlled, parallel-group study, patients (n = 204) were randomized to teneligliptin 20 mg or placebo once daily added to their stable pioglitazone therapy. This was followed by a 40-week, open-label period during which all patients received teneligliptin once daily. The primary end-point was the change in hemoglobin A1c (HbA1c) from baseline to week 12.

Results

Patients in the teneligliptin group showed significantly greater reductions in HbA1c compared with the placebo group at week 12 (P < 0.001). The chang

SUBMITTER: Kadowaki T 

PROVIDER: S-EPMC4020253 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature